Skip to content
Triangle logo TriangleGet started
← Study library

NCT00030719 · CITED IN SOURCE DOCUMENTS

Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
UNKNOWN
Registry last update
2014-06-24

RATIONALE: Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining isotretinoin and monoclonal antibodies may kill any remaining tumor cells following surgery. It is not yet known which treatment regimen is more effective in treating neuroblastoma. PURPOSE: This randomized phase III trial is studying how well combination chemotherapy with or without filgrastim before surgery, high-dose chemotherapy, and radiation therapy followed by isotretinoin with or without monoclonal antibody work in treating patients with neuroblastoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: * Diagnosis of neuroblastoma according to International Neuroblastoma Staging System * Stage 2 or 3 with MycN amplification * Stage 4 * Tumor material available for determination of biological prognostic factors PATIENT CHARACTERISTICS: Age: * 1 to 20 at diagnosis Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Bilirubin less than 3 times normal * ALT less than 3 times normal Renal: * Creatinine less than 1.5 mg/mL * Creatinine clearance and/or glomerular filtration rate at least 60 mL/min Cardiovascular: * Shortening fraction at least 28% OR * Ejection fraction at least 55% * No clinical congestive heart failure Pulmonary: * Chest x-ray normal * Oxygen saturation normal Other: * HIV negative * No Brock grade 2 or greater * No uncontrolled infections requiring IV antivirals, antibiotics, or antifungals * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No more than 1 prior chemotherapy regimen for localized unresectable disease * No concurrent anthracyclines * No other concurrent chemotherapy Endocrine: * Not specified Radiotherapy: * Not specified Surgery: * Not specified Other: * No other concurrent investigational therapy
healthy Volunteers
false
maximum Age
20 Years
minimum Age
1 Year
sex
ALL
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
interventions
  1. name
    filgrastim
    type
    BIOLOGICAL
  2. name
    monoclonal antibody Ch14.18
    type
    BIOLOGICAL
  3. name
    busulfan
    type
    DRUG
  4. name
    carboplatin
    type
    DRUG
  5. name
    cyclophosphamide
    type
    DRUG
  6. name
    etoposide
    type
    DRUG
  7. name
    isotretinoin
    type
    DRUG
  8. name
    melphalan
    type
    DRUG
  9. name
    vincristine sulfate
    type
    DRUG
  10. name
    bone marrow ablation with stem cell support
    type
    PROCEDURE
  11. name
    conventional surgery
    type
    PROCEDURE
  12. name
    peripheral blood stem cell transplantation
    type
    PROCEDURE
Study design
allocation
RANDOMIZED
primary Purpose
TREATMENT
Enrollment
count
175
type
ESTIMATED
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Event-free survival at 3 years
  2. measure
    Mean number of febrile events during induction
secondary Outcomes
  1. measure
    Response rate assessed by the International Neuroblastoma Response Criteria after 4 and 8 induction chemotherapy courses
  2. measure
    Event-free survival at 5 years
  3. measure
    Overall survival
  4. measure
    Toxicity
  5. measure
    Biological factors (i.e., MycNM amplification, 1p deletion, ploidy, 17 q+, CD44, and Trk-A)
  6. measure
    Serum concentrations of lactic dehydrogenase, ferritin, neurone specific enolase
  7. measure
    Urinary catecholamines at diagnosis
Full study description
brief Summary
RATIONALE: Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining isotretinoin and monoclonal antibodies may kill any remaining tumor cells following surgery. It is not yet known which treatment regimen is more effective in treating neuroblastoma. PURPOSE: This randomized phase III trial is studying how well combination chemotherapy with or without filgrastim before surgery, high-dose chemotherapy, and radiation therapy followed by isotretinoin with or without monoclonal antibody work in treating patients with neuroblastoma.
detailed Description
OBJECTIVES: * Compare the efficacy of myeloablative therapy with busulfan and melphalan vs carboplatin, etoposide, and melphalan, in terms of 3- and 5-year event-free survival (EFS), progression-free survival (PFS), and overall survival (OS), in patients with high-risk neuroblastoma. * Compare the 3-year EFS in these patients treated with isotretinoin with or without monoclonal antibody Ch14.18 after myeloablative therapy. * Determine the response at metastatic sites after induction chemotherapy in these patients. * Determine the effect of metastatic disease response after induction chemotherapy on EFS, PFS, and OS in these patients. * Compare the toxicity and episodes of febrile neutropenia in patients treated with induction chemotherapy with or without filgrastim (G-CSF). * Determine the effect of elective hematopoietic support with G-CSF during induction chemotherapy on peripheral blood stem cell collection in these patients. * Compare the acute and long-term toxic effects of the 2 myeloablative therapy regimens in these patients. * Determine the effect of radiotherapy on pre-surgical tumor volume at the primary site on local control, EFS, PFS, and OS in these patients. * Determine the tolerability of isotretinoin with or without monoclonal antibody Ch14.18 after myeloablative therapy in these patients. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to disease stage (2 or 3 with MycN amplification vs 4). Patients are randomized to 1 of 8 treatment arms: Arm I: * Patients receive induction chemotherapy comprising vincristine IV, carboplatin IV over 1 hour, and etoposide IV over 4 hours on days 1 and 41; vincristine IV and cisplatin IV over 24 hours on days 11, 31, 51, and 71; and vincristine IV on days 21 and 61 and cyclophosphamide IV and etoposide over 4 hours on days 21, 22, 61, and 62. Patients receive filgrastim (G-CSF) subcutaneously on days 3-8, 12-18, 23-28, 32-38, 43-48, 52-58, 63-68, and 72 until peripheral blood stem cell (PBSC) collection. * Patients undergo PBSC collection beginning on day 80. Patients then undergo surgery on day 95. * Patients receive myeloablative therapy comprising oral busulfan 4 times daily on days -6 to -3 and melphalan IV over 15 minutes on day -2. Patients undergo PBSC infusion on day 0. * Patients undergo radiotherapy in 14 fractions over 21 days. * Beginning within 30 days after radiotherapy, patients receive oral isotretinoin twice daily on days 1-14. Treatment repeats every 28 days for 6 courses. Arm II: * Patients receive induction chemotherapy as in arm I, but with no G-CSF. Patients then undergo PBSC collection and surgery as in arm I. Patients receive myeloablative therapy and undergo PBSC infusion as in arm I. Patients undergo radiotherapy as in arm I. * Patients receive oral isotretinoin twice daily on days 1-14 and monoclonal antibody Ch14.18 IV over 8 hours on days 1-5. Treatment repeats every 28 days for 6 courses for isotretinoin and every 28 days for 5 courses for monoclonal antibody Ch14.18. Arm III: * Patients receive induction chemotherapy and G-CSF as in arm I. Patients then undergo PBSC collection and surgery as in arm I. Patients receive myeloablative therapy and undergo PBSC infusion as in arm I. Patients undergo radiotherapy as in arm I. Patients receive isotretinoin as in arm I. Arm IV: * Patients receive induction chemotherapy as in arm II. Patients then undergo PBSC collection and surgery as in arm I. Patients receive myeloablative therapy and undergo PBSC infusion as in arm I. Patients undergo radiotherapy as in arm I. Patients receive isotretinoin and monoclonal antibody Ch14.18 as in arm II. Arm V: * Patients receive induction chemotherapy and G-CSF as in arm I. * Patients receive myeloablative therapy comprising carboplatin IV continuously and etoposide IV continuously on days -7 to -4 and melphalan IV over 15 minutes on days -7 to -5. Patients undergo PBSC infusion on day 0. * Patients undergo radiotherapy as in arm I. Patients receive isotretinoin as in arm I. Arm VI: * Patients receive induction chemotherapy as in arm II. Patients receive myeloablative therapy and undergo PBSC infusion as in arm V. Patients undergo radiotherapy as in arm I. Patients receive isotretinoin and monoclonal antibody Ch14.18 as in arm II. Arm VII: * Patients receive induction chemotherapy and G-CSF as in arm I. Patients receive myeloablative therapy and undergo PBSC infusion as in arm V. Patients undergo radiotherapy as in arm I. Patients receive isotretinoin as in arm I. Arm VIII: * Patients receive induction chemotherapy as in arm II. Patients receive myeloablative therapy and undergo PBSC infusion as in arm V. Patients undergo radiotherapy as in arm I. Patients receive isotretinoin and monoclonal antibody Ch14.18 as in arm II. Patients on all treatment arms are followed every 6 months for 3 years and then annually for 2 years. Peer Reviewed and Funded or Endorsed by Cancer Research UK PROJECTED ACCRUAL: Approximately 175 patients per year will be accrued for this study.
Source references
references
  1. citation
    Ladenstein R, Valteau-Couanet D, Brock P, Yaniv I, Castel V, Laureys G, Malis J, Papadakis V, Lacerda A, Ruud E, Kogner P, Garami M, Balwierz W, Schroeder H, Beck-Popovic M, Schreier G, Machin D, Potschger U, Pearson A. Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol. 2010 Jul 20;28(21):3516-24. doi: 10.1200/JCO.2009.27.3524. Epub 2010 Jun 21.
    pmid
    20567002
    type
    RESULT
  2. citation
    Veal GJ, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D, Brock P, Ladenstein R, Vassal G. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. Eur J Cancer. 2012 Nov;48(16):3063-72. doi: 10.1016/j.ejca.2012.05.020. Epub 2012 Jun 26.
    pmid
    22742881
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-6241b3e751844fc6551c
      requested nct id
      NCT00030719
      primary nct id
      NCT00030719
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      308a08f515ba694b00db3851eb2531e1ed582dada1d1a75d9bb7c00853441821
      payload sha256
      081eb5c6cb444b971e795fa2f4c8392e3d8c5fa88f04163827fa891f487aeba7
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-6241b3e751844fc6551c
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00030719
      occurrences
      1. context exact
        ve study of Curie scoring was performed on 123I-MIBG scans obtained from high-risk patients who had been prospectively enrolled in the <a href="/clinicaltrials/NCT00030719">SIOPEN/HR-NBL1 (NCT00030719)</a> trial. Scans of nine anatomical regions were evaluated for bone metastases and a tenth region for all sites of soft tissue di
        end
        194839
        exact text
        NCT00030719
        start
        194828
      2. context exact
        performed on 123I-MIBG scans obtained from high-risk patients who had been prospectively enrolled in the <a href="/clinicaltrials/NCT00030719">SIOPEN/HR-NBL1 (NCT00030719)</a> trial. Scans of nine anatomical regions were evaluated for bone metastases and a tenth region for all sites of soft tissue disease. Each region was scored
        end
        194868
        exact text
        NCT00030719
        start
        194857
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/d023d406c02e860e22.html
      source file sha256
      308a08f515ba694b00db3851eb2531e1ed582dada1d1a75d9bb7c00853441821
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:22:09.227808+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      5a0bcb41a33182c1bb316ea92b74ca10701add33aec3077a54a565e6d80cbf53
      source title
      Neuroblastoma Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: April 28, 2025
        datetime
        2025-04-28T12:00:00Z
        display
        April 28, 2025

    Preserved source evidence · Not medical advice